About Re-Stem
Re-Stem is a company based in Suzhou (China) founded in 2012 by Benno Jiao. It operates as a B2B and Research and Development. Re-Stem offers products and services including RE-EnableTM, RE-AGN 2.0, RE-KneewTM, and Cell Banking. Re-Stem operates in a competitive market with competitors including Horizon Therapeutics, NuVasive, Ensoma, Osteal Therapeutics and ZetaGen, among others.
- Headquarter Suzhou, China
- Founders Benno Jiao
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name บริษัท รีสเต็ม แมเนจเม้นท์ จำกัด
- Jurisdiction Na, Maharashtra, India
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Re-Stem
Re-Stem offers a comprehensive portfolio of products and services, including RE-EnableTM, RE-AGN 2.0, RE-KneewTM, and Cell Banking.
Treatment for spinal cord injury recovery through cell-based intervention.
Therapy targeting lung and liver cancers with proprietary technology.
Autologous therapy for knee osteoarthritis using mesenchymal stem cells.
Storage and supply of stem cells for research and enterprises.
Funding Insights of Re-Stem
Investments & Acquisitions by Re-Stem
Financial Statements - Re-Stem
Re-Stem Comparisons
Competitors of Re-Stem
Re-Stem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, NuVasive, Ensoma, Osteal Therapeutics and ZetaGen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Smart surgical devices for spinal surgery are developed.
|
|
| domain | founded_year | HQ Location |
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool
|
|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for bone regeneration are developed.
|
|
| domain | founded_year | HQ Location |
Drugs for muscle, bone, and joint diseases are developed.
|
Latest news on Re-Stem
Frequently Asked Questions about Re-Stem
Re-Stem was founded in 2012.
Re-Stem is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.
Benno Jiao is the current CEO of Re-Stem. They have also founded this company.
RE-Stem Biotech is a biotechnology company that focuses on researching and developing cell therapies targeting osteoarthritis, spinal cord injury, and various cancers. They utilize a hybrid technology platform for stem cell and immune cell therapies, cell banking, and supplying stem cells to other enterprises. Based in China and Thailand, they collaborate with an international team of scientists and executives. Their activities include creating proprietary treatments like RE-EnableTM and partnering for clinical applications, serving research and medical sectors.
Re-Stem's top competitors include Horizon Therapeutics, NuVasive and Ensoma.
Re-Stem offers RE-EnableTM, RE-AGN 2.0, RE-KneewTM, and Cell Banking.